The Denver Post – Boulder-based Array BioPharma Inc.‘s shares jumped after the company said early Wednesday that a Phase 3 clinical trial for its cancer drug binimetinib was successful. Continue reading.
The Denver Post – Boulder-based Array BioPharma Inc.‘s shares jumped after the company said early Wednesday that a Phase 3 clinical trial for its cancer drug binimetinib was successful. Continue reading.